Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer

Lancet

Volumn 349, Issue 9049, 1997, Pages 389-392

  Yiannakou, J Y ^a   Newland, P ^a   Calder, F ^a   Kingsnorth, A N ^a   Rhodes, Jonathan M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAM 17.1; LECTIN; MUCIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; JAUNDICE; MAJOR CLINICAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERODIAGNOSIS; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 0031047418     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80011-6     Document Type: Article

References (14)

1. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas Am J Gastroenterol 1986; 90: 343-49.
2. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92: 60-67.
3. Haglund C, Roberts P, Kuusela P, Scheinin TM, Makela O, Jalanko H. Evaluation of CA 19-9 as a tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197-202.
4. Molina LM, Diez M, Cava MT. Tumour markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50. Int J Biol Markers 1990; 5: 127-32.
5. Cooper EH, Forbes MA, Taylor M. An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease. Br J Cancer 1990; 62: 1004-05.
6. Kawa S, Oguchi GL, Kobayashi T, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991; 64: 899-902.
7. Umeyama K, Takeuchi T, Chung YS, et al. Clinical evaluation of measurement of pancreatic cancer associated antigen, SPan-1. J Jap Panc Soc 1988; 3: 528-39.
8. Parker N, Makin CA, Ching CK, et al. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 1992; 70: 1062-68.
9. Thompson JN. Diagnosing cancer of the pancreas BMJ 1990; 301: 1164.
10. Rhodes JM, Ching CK. Serum diagnostic tests for pancreatic cancer. In: Neoptolemos JP, ed. Cancer of the pancreas. London: Bailliere Tindall Clinical Gastroenterology, 1990: 833-52.
11. Raouf AH, Parker N, Iddon D, et al. Ion-exchange chromatography of purified mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut 1991; 32: 1139-45.
12. Moosa AR, Gadd M, Lavelle-Jones M. Surgical treatment of exocrine pancreatic cancer. In: Go VWI, ed. The exocrine pancreas: biology, pathology, and diseases. New York: Raven, 1986: 713-25.
13. Richter JM, Christensen MR, Rustgi AK, Silverstein MD. The clinical utility of the CA 19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss: cost-effectiveness analysis. Arch Intern Med 1989; 149: 2292-97.
14. Bovo P, Rigo L, Togni M, et al. Rapid diagnosis of pancreatic cancer by combination of ultrasonography and serum tumour markers CA 19-9 and CA 50. Ital J Gastroenterol 1993; 25: 477-81.